Evommune, Inc. (EVMN) Market Cap & Valuation Ratios
Evommune, Inc. (EVMN) has a market cap of $185.1M and a price-to-sales ratio of 18.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EVMNEvommune, Inc.Follow EVMN — free
—
Price chart with a free account
- Market cap
- 185.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Dec, in 46 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| EVMN | 0.2 | — | — | — | — | +86% | — | -47% |
| CTNM | 0.3 | — | — | — | — | — | — | -35% |
| TTRX | 0.3 | — | — | — | -1.4% | — | — | — |
| BNTC | 0.3 | — | — | — | -5.5% | — | — | — |
| PRLD | 0.3 | — | 6.2 | — | -11.5% | +220% | -301% | -86% |
| IRD | 0.3 | — | 24.0 | — | -12.2% | -36% | — | — |
| QNRX | 0.3 | — | — | — | -5.4% | — | — | — |
| AMRN | 0.3 | — | — | — | 6.0% | -15% | -22% | -13% |
| ABEO | 0.3 | — | 4.7 | — | — | — | -328% | -157% |
| LYEL | 0.2 | — | 963.0 | — | — | -55% | — | -142% |
| FHTX | 0.1 | — | 1.4 | — | — | +52% | -198% | — |
| Median of these 10 | — | 6.2 | — | -5.5% | -15% | -249% | -86% |
.
Growth vs. price
each dot a company · hover or tap for valuesEvommune, Inc. — questions
- What is Evommune, Inc.'s market cap?
- $185.1M.
- What is Evommune, Inc.'s price-to-sales ratio?
- 18.5.
Every figure on this page comes from Evommune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.